Therefore, the purposes of this study were (1) to evaluate the levels of PACAP and VIP in the serum in PD patients and healthy controls, and (2) to investigate whether there is any correlation between neuropeptide levels and non-motor symptoms in patients with PD. This evidence concerns the gene ADCYAP1 and Parkinson disease.